Kodiak Sciences Shares Surge on Bullish Analyst Upgrades

Kodiak Sciences Inc. witnessed a dramatic trading session as its stock soared more than 11% to reach $21.05. The biotechnology firm’s shares hit a fresh 52-week peak of $21.17 during regular trading and maintained this upward trajectory in after-hours activity. This substantial rally was primarily fueled by several optimistic analyst upgrades that reinforced confidence in the company’s developmental pipeline.

The intense investor focus on Kodiak’s pipeline stems from several approaching clinical data readouts:

• GLOW2 Study (Diabetic Retinopathy): Topline results expected Q1 2026
• DAYBREAK Study (Tarcocimab): Data anticipated Q3 2026
• DAYBREAK Study (KSI-501): Findings scheduled for Q3 2026
• KSI-101 Read more...